Advancing cardiovascular biology and medicine via proteomics: Opportunities and present challenges of cardiovascular proteomics

Circulation

Volumn 121, Issue 21, 2010, Pages 2326-2328

  Ping, Peipei ^a   Chan, Daniel W ^b   Srinivas, Pothur ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

^c NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Biology; Biomedical technologies; Medicine; Proteomics

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; HORMONE PRECURSOR; LIPOPROTEIN; PHOSPHOLIPASE A2; PROTEOME; TRANSCRIPTOME;

ACUTE CORONARY SYNDROME; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; GENOME; HUMAN; MEDICAL RESEARCH; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; PROTEIN MODIFICATION; PROTEOMICS;

CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; CARDIOVASCULAR SYSTEM; HUMANS; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (U.S.); PROTEOMICS; UNITED STATES;

EID: 77953226728     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.949230     Document Type: Article

References (11)

1. Lin C, Mathur R, Aizikov K, O'Connor PB. First signal on the cryogenic Fourier-transform ion cyclotron resonance mass spectrometer. J Am Soc Mass Spectrom. 2007;18:2090-2093. (Pubitemid 350161322)
2. Ro KW, Liu J, Knapp DR. Plastic microchip liquid chromatography-matrix- assisted laser desorption/ionization mass spectrometry using monolithic columns. J Chromatogr A. 2006;1111:40-47.
3. Stanislaus R, Arthur JM, Rajagopalan B, Moerschell R, McGlothlen B, Almeida JS. An open-source representation for 2-DE-centric proteomics and support infrastructure for data storage and analysis. BMC Bioinfor-matics. 2008;9:4.
4. Keller A, Eng J, Zhang N, Li XJ, Aebersold R. A uniform proteomics MS/MS analysis platform utilizing open XML file formats. Mol Syst Biol. 2005;1:2005.0017.
5. Deutsch EW, Lam H, Aebersold R. PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows. EMBO Rep. 2008; 9:429-434.
6. Krutzik PO, Crane JM, Clutter MR, Nolan GP. High-content single-cell drug screening with phosphospecific flow cytometry. Nat Chem Biol. 2008;4:132-142.
7. Udugamasooriya DG, Dineen SP, Brekken RA, Kodadek T. A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity. J Am Chem Soc. 2008;130:5744-5752.
8. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, Antman EM, Lee RT. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation. 2004;109:2186-2190.
9. Sabatine MS, Morrow DA, Higgins LJ, MacGillivray C, Guo W, Bode C, Rifai N, Cannon CP, Gerszten RE, Lee RT. Complementary roles for biomarkers of biomechanical strain ST2 and N-terminal prohormone B-type natriuretic peptide in patients with ST-elevation myocardial infarction. Circulation. 2008;117:1936-1944.
10. Mega JL, Morrow DA, de Lemos JA, Mohanavelu S, Cannon CP, Sabatine MS. Thrombus precursor protein and clinical outcomes in patients with acute coronary syndromes. J Am Coll Cardiol. 2008;51: 2422-2429.
11. Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J, for the PEACE Investigators. Prognostic utility of lipoprotein-associated phospholipase A2for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol. 2007;27:2463-2469.